176 related articles for article (PubMed ID: 2759162)
1. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
2. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
[TBL] [Abstract][Full Text] [Related]
4. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
6. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.
Miserez AR; Günes I; Müller-Brand J; Walther E; Fridrich R; Mäcke H
Eur J Cancer; 1991; 27(2):126-31. PubMed ID: 1827273
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA 15.3 and carcinoembryonic antigen.
Bieglmayer C; Szepesi T; Neunteufel W
Cancer Lett; 1988 Nov; 42(3):199-206. PubMed ID: 2461250
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
11. Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.
Stierer M; Rosen HR; Forster E; Moroz C
Breast Cancer Res Treat; 1991 Nov; 19(3):283-8. PubMed ID: 1777647
[TBL] [Abstract][Full Text] [Related]
12. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis].
Delbrück H; Hagen-Aukamp C; Braun G
Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152
[TBL] [Abstract][Full Text] [Related]
13. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
15. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.
Boccardo F; Bombardieri E; Zanardi S; Valenti G; Zanaboni F; Valtolina M; Seregni E; Crippa F
Int J Biol Markers; 1991; 6(1):12-20. PubMed ID: 1856512
[TBL] [Abstract][Full Text] [Related]
16. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
18. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer.
Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF
Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
